n-methyl-3,4-methylenedioxyamphetamine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cozzi, NV; Sewell, RA | 1 |
| Benkovic, S; Gordon, MN; Miller, D; O'Callaghan, JP; Pennypacker, KR; Yang, X | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA | 1 |
| Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato-Faure, V; Thobois, S; Tremblay, L | 1 |
4 other study(ies) available for n-methyl-3,4-methylenedioxyamphetamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
More about parkinsonism after taking ecstasy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Basal Ganglia; Dopamine Agents; Hallucinogens; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary | 1999 |
Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine- and trimethyltin-induced brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; DNA-Binding Proteins; Dopamine Agents; Fos-Related Antigen-2; Immunohistochemistry; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Time Factors; Transcription Factors; Trimethyltin Compounds | 2000 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Dopamine Agents; Macaca fascicularis; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Serotonin; Serotonin Agents; Statistics, Nonparametric; Time Factors; Tyrosine 3-Monooxygenase | 2018 |